Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD
Author:
Affiliation:
1. Department of Gastroenterology; Herlev Hospital; Herlev; Denmark
2. Institute for Inflammation Research; Rigshospitalet, University Hospital of Copenhagen; Copenhagen; Denmark
Publisher
Wiley
Subject
Pharmacology (medical),Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2012.05204.x/fullpdf
Reference8 articles.
1. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting reinduction outcome in IBD;Ben-Horin;Aliment Pharmacol Ther,2012
2. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease;Steenholdt;Inflamm Bowel Dis,2012
3. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab;Bendtzen;Arthritis Rheum,2006
4. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease;Ainsworth;Am J Gastroenterol,2008
5. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease;Steenholdt;Scand J Gastroenterol,2011
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2018-02-16
2. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2018-02-16
3. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases;Alimentary Pharmacology & Therapeutics;2017-10-13
4. Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview;Drugs;2017-02-23
5. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease;Expert Opinion on Drug Safety;2016-12-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3